SAN DIEGO, July 28, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company will present to an audience of principals and key decision makers of broker/dealers and financial firms at the FSXinterlinked Financial Investment Conference to be held at the Four Season Westlake Village, California from July 30-August 2nd, 2014. The presentation will take place on Thursday, July 31, 2014 at 1:57pm.
The Company's investor presentation will include the following:
-
Overview of the Company's business model
-
Upcoming milestones
-
Details on the Company's commercial efforts
-
Overview of its four commercial products
-
Management expertise and profile
To arrange a one-on-one meeting with management, please contact Lynnette Dillen at ldillen@innovuspharma.com or 1-858-964-5123.
About FSX Investment Conference
FSX is the premier investment conference organization in the United States. Founded in 1983, FSX is a national organization comprised of independent FINRA broker/dealer firms. Through a series of regularly scheduled investment conferences, FSX brings these firms together with the purpose of sharing information and showcasing investment opportunities.
More information can be found at http://www.fsxinterlinked.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra® for female arousal, and EjectDelay™ for premature ejaculation, and has a total of four marketed products in this space including CIRCUMSerum™ (for sales outside the U.S. only) and Zestra® Glide.
For more information, go to www.innovuspharma.com.
INNOVUS PHARMA'S FORWARD-LOOKING Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra®, to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Innovus Pharma Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930
Lynnette Dillen
EVP & CFO
Innovus Pharmaceuticals
ldillen@innovuspharma.com
T: 858-964-5123
